



Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Actemra (tocilizumab)**. Please complete and fax this form back to Kaiser Permanente within 24 hours [fax: [1-866-331-2104](tel:1-866-331-2104)]. If you have any questions or concerns, please call [1-866-331-2103](tel:1-866-331-2103). **Requests will not be considered unless this form is complete. The KP-MAS Formulary can be found at: <http://pithelp.appl.kp.org/MAS/formulary.html>**

1 – Patient Information

Patient Name: _____ Kaiser Medical ID#: _____ Date of Birth: _____

2 – Provider Information

Provider Name: _____ Specialty: _____ Provider NPI: _____

Provider Address: _____

Provider Phone #: _____ Provider Fax #: _____

Please check the boxes that apply:

- Initial Request Continuation of Therapy Request

3 – Pharmacy Information

Pharmacy Name: _____ Pharmacy NPI: _____

Pharmacy Phone # _____ Pharmacy Fax #: _____

4 – Drug Therapy Requested

Drug 1: Name/Strength/Formulation: _____

Sig: _____

Drug 2: Name/Strength/Formulation: _____

Sig: _____

5– Diagnosis/Clinical Criteria

1. Does the member have diagnosis of one of the following? **AND**
 - Rheumatoid Arthritis (RA)
 - Systemic Juvenile Idiopathic Arthritis (SJIA)
 - Polyarticular juvenile idiopathic arthritis (pJIA)
 - Other: _____
2. Was there therapeutic failure on oral methotrexate? **AND**
 - No Yes
3. Was there therapeutic failure to one of the preferred agents? (e.g. Enbrel, Humira) **AND**
 - No Yes
4. If this is being used for Rheumatoid Arthritis (RA), Polyarticular Juvenile Idiopathic Arthritis (PJIA) or Systemic Juvenile Idiopathic Arthritis (SJIA):
 - a. Did the patient try and fail Methotrexate? **OR**
 - No Yes
 - b. Will this medication be used in conjunction with Methotrexate? **OR**
 - No Yes
 - c. Does the patient have a contraindication to Methotrexate? (e.g., alcohol abuse, cirrhosis, chronic liver disease, or other contraindication) **AND**
 - No Yes
 - d. Did the patient try and fail another DMARD (other than Methotrexate), such as azathioprine, d-penicillamine, cyclophosphamide, cyclosporine, gold salts, hydroxychloroquine, leflunomide, sulfasalazine, or tacrolimus?
 - No Yes

6 – Provider Sign-Off

Additional Information – Please provide any additional information that should be taken into consideration.

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Provider Signature:

Date:

Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility